Xet CR Plus 25 Capsule contains a combination of Paroxetine 25 mg and Clonazepam 0.25 mg, formulated to manage conditions involving anxiety, depression, and related disorders. Paroxetine, a selective serotonin reuptake inhibitor (SSRI), functions by increasing serotonin levels in the brain, thereby improving mood, emotional stability, and reducing symptoms of depression and anxiety. Clonazepam, a benzodiazepine, exhibits anxiolytic, anticonvulsant, and muscle-relaxant properties by enhancing the effect of gamma-aminobutyric acid (GABA), a neurotransmitter that inhibits excessive neuronal activity. The sustained-release formulation of Paroxetine in Xet CR Plus 25 ensures a gradual and consistent release, promoting stable plasma concentrations and minimizing side effects. This combination is particularly beneficial for patients requiring rapid relief from acute anxiety symptoms alongside long-term antidepressant therapy. Xet CR Plus 25 should be used under strict medical supervision due to the potential for dependence associated with Clonazepam and the risk of serotonin syndrome with Paroxetine. It is contraindicated in patients with hypersensitivity to either component, severe hepatic impairment, or concurrent use of monoamine oxidase inhibitors (MAOIs). Common side effects may include dizziness, drowsiness, gastrointestinal disturbances, and headache. Dosage adjustments should be individualized based on clinical response and tolerability.